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Abstract
Aims/hypothesis Microvascular dysfunction is associated
with end-organ damage. Macular oedema is an important
component of diabetic retinopathy. Macular thickness can be
accurately quantified by optical coherence tomography
(OCT), enabling accurate assessment of the macular prior
to clinically apparent abnormalities. We investigated wheth-
er macular (fovea) thickness in non-diabetic individuals is
related to the microvascular variables controlling fluid
filtration across a blood vessel wall, in particular capillary
pressure and the microvascular filtration capacity (Kf).
Methods We recruited 50 non-diabetic individuals (25 men,
25 women; age range: 26–78 years; BMI range: 20–46 kg/m2).
Fovea thickness was assessed by OCT. Microvascular
assessments included: finger nailfold capillary pressure; Kf;
microvascular structural assessments, i.e. skin vasodilatory
capacity, minimum vascular resistance (MVR) and microvas-
cular distensibility; and endothelial function.
Results At 214.6 (19.9) µm (mean [SD]), fovea thickness
was within normal range. Capillary pressure, adjusted for
BMI, was associated with fovea thickness (standardised beta
0.573, p=0.006, linear regression). Fovea thickness was not
associated with Kf, microvascular structural assessments or
endothelial function. Capillary pressure was still associated
with fovea thickness when adjusted for microvascular
variables (Kf, vasodilatory capacity, MVR, microvascular
distensibility or endothelial function), or for risk factors for
diabetes (systemic blood pressure, insulin sensitivity,
inflammation, glycaemic status and lipids) and age.
Conclusions/interpretation Capillary pressure, a key deter-
minant of movement of fluid across a blood vessel wall, is
associated with fovea thickness in non-diabetic individuals.
This suggests that with regard to potential preventative or
therapeutic targets, attention should be directed at the
mechanisms determining retinal microvascular pressure.
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Abbreviations
CSMO Clinically significant macular oedema
ITT Insulin tolerance test
Kf Microvascular filtration capacity
LDPI Laser Doppler perfusion imager
MVR Minimum vascular resistance
OCT Optical coherence tomography
Introduction
The microcirculation is the site where nutrients and waste
products are exchanged between the circulation and tissues.
Normal microcirculation is vital for tissue health, while
abnormalities are associated with disease. In the Athero-
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sclerosis Risk in Communities and other epidemiological
studies, clinically apparent retinal structural microvascular
abnormalities (including non-diabetic retinopathy) were, for
example, independently related to risk of diabetes [1–5],
impaired fasting hyperglycaemia [1, 6], stroke [7–11],
magnetic resonance imaging-defined subclinical cerebral
infarcts [12], progression of cerebral small vessel disease
[1], congestive heart failure [4], coronary heart disease and
acute myocardial infarction [5, 8, 11], left ventricular
hypertrophy [13] and cardiovascular mortality rates [14].
However, it is not only these clinically apparent
structural abnormalities in the retinal microcirculation that
are related to clinical outcomes and/or risk. In the
periphery, functional impairments in the small vessels, such
as impaired endothelial function of the forearm resistance
blood vessels or impaired skin microcirculatory responsive-
ness, are associated with cardiovascular risk factors [15, 16]
and end-organ damage (intraventricular septal thickness or
urinary albumin excretion) [17].
Indeed, graded abnormalities in the reactive hyperaemic
response of the skin occur across levels of urinary albumin
excretion rate from 2 to 20 µg/min, i.e. within the normal
range [18]. These associations indicate that subtle abnor-
malities of microvascular function may run parallel to early
evidence of end-organ damage even prior to presentation of
clinical disorders.
Diabetic retinopathy remains a leading cause of blind-
ness with maculopathy being the most resistant to amelio-
ration. Macular (fovea) thickening is a preclinical sign of
macular oedema, which can be quantified using the new,
revolutionary technique of retinal optical coherence tomog-
raphy (OCT).
This study investigated the mechanisms underlying
preclinical changes in fovea thickness, and in particular
the roles of the variables that can control fluid movement
across the blood vessel wall, e.g. capillary pressure and
microvascular filtration capacity (Kf).
Methods
Participants We recruited 50 non-diabetic individuals (age
range 26 to 78 years) from the local community by
advertisements for this study (participant characteristics,
see Table 1). Exclusion criteria were diabetes, overt
cardiovascular disease, Raynaud’s phenomenon, age less
than 18 or over 80 years, and use of any anti-hypertensive,
oral hypoglycaemic or lipid-lowering therapies. Seven of
the participants had the metabolic syndrome, as defined by
the International Diabetes Federation [19]. None of the
participants had clinically defined microalbuminuria. Only
one participant smoked (cigars), but this participant
refrained from smoking on the mornings of the study.
Ethics approval was granted by the Local Exeter and North
Devon Medical Research Ethics Committee, and written
informed consent was obtained from all participants. The
studies conformed to the principles outlined in the
Declaration of Helsinki.
Procedures Participants attended the study visits in the
morning following an overnight fast. The following assess-
ments were spread over two to three mornings: macular
thickness, retinal photography, capillary pressure, Kf,
microvascular structural assessments (vasodilatory capacity,
minimum vascular resistance [MVR], microvascular dis-
tensibility), resting skin perfusion, microvascular endothe-
lial function and supine blood pressure (mean of three
measurements taken at 1 min intervals). The vascular
assessments were performed in temperature-controlled
microvascular laboratories with the participants in a supine
position following a 30 min acclimatisation period.
Macular thickness OCT was used to quantify retinal
thickness (Stratus OCT 3000; Carl Zeiss, Welwyn Garden
City, UK) using the fast macular thickness scanning
protocol following pupil dilation in both eyes. OCT mea-
sures the macular thickness between the vitreoretinal
interface and the interface between the inner and outer
photoreceptors segments by changes in reflectivity from the
Table 1 Participant characteristics
Variables Mean (SD) Range
Total sample (n) 50 (25)
Men (n) 25
Age (years) 53.5 (11.8) 26 to 78
BMI (kg/m2) 28.6 (6.1) 20 to 46
Waist circumference (cm) 94.4 (15.8) 69 to 139
Systolic blood pressure (mmHg) 124 (16) 87 to 162
Diastolic blood pressure (mmHg) 75.2 (9.4) 59 to 95
Fasting glucose (mmol/l) 4.9 (0.5) 4.0 to 6.9
HbA1c (%) 5.5 (0.4) 3.9 to 6.3
Total cholesterol (mmol/l) 5.37 (0.84) 3.7 to 7.4
HDL-cholesterol (mmol/l) 1.54 (0.42) 0.72 to 2.32
LDL-cholesterol (mmol/l) 3.21 (0.62) 2.17 to 5.22
Triacylglycerol (mmol/l) 1.19 (0.46) 0.46 to 2.40
ACR (mg/mmol) 0.62 (0.27) 0.22 to 1.44
AER(µg/min) 5.35 (2.82) 2.11 to 15.36
Inflammation markers
C-reactive protein (ng/ml) 982 (1,293) 24 to 5,578
Measures of insulin sensitivity
ITT (mmol l−1 min−1) −0.22 (0.08) −0.53 to −0.11
Insulin sensitivity (HOMA) (%) 130 (74) 16 to 318
ACR, albumin:creatinine ratio
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reflected light (original light source: broad bandwidth near
infrared light beam with central wavelength of 820 nm).
The Stratus OCT software (version 4.0.7) automatically
determines the thickness of the subdivisions of the macula
(fovea; inner and outer quadrants of the superior, nasal,
inferior and temporal regions) and the volume of the total
macular area. The fovea was defined as the central disc of
the scan, with a radius of 500 µm. This technique is
reproducible in healthy participants [20]. In our hands, the
intra-individual coefficient of variation for the assessment
of fovea thickness was 2.6% (182.0 [4.8] µm, mean [SD])
determined from one participant on four separate occasions.
Capillary pressure Finger nailfold capillary pressure was
measured following direct cannulation of the apex of the
capillary loop with a glass micropipette. Dynamic record-
ings of capillary pressure were achieved using an electronic
resistance feedback servo-nulling system [21]. Day-to-day
intra-participant variation of the measurement of capillary
pressure was 5.2% (3.6%) in six individuals studied on three
separate occasions.
Microvascular filtration capacity Kf was determined using
strain-gauge plethysmography (Filtrass 2001; Domed Med-
izintechnik, Munich, Germany) [22]. The system uses an
occlusion cuff placed proximal (thigh) to the filtrass sensor
to monitor changes in calf circumference and hence volume
in response to increases in venous congestion pressure. The
calf circumference is continuously monitored throughout a
series of small pressure increases of 8 mmHg that in total
do not exceed diastolic pressure. As the venous congestion
pressure increases, the net movement of fluid across the
vessel wall into the interstitium, that is fluid filtration,
increases. The relationship between fluid filtration and cuff
pressure is linear, with the slope representing Kf. The mean
day-to-day intra-participant variation in the measurement of
Kf using this system was 7.1% in two healthy participants
assessed on four separate occasions (2.37±0.21×10−3 and
2.90±0.15×10−3 ml min−1 [100 ml]−1 mmHg−1, mean ± SD,
for participants 1 and 2 respectively).
Structural microvascular assessments: vasodilatory capac-
ity, minimum vascular resistance and microvascular dis-
tensibility Maximum hyperaemia was assessed by heating a
small area of skin to 42 to 44°C [23], which induces
maximum hyperaemia and reflects the vasodilatory capacity
of the skin microcirculation. This was achieved by attach-
ing a small brass heater (area 0.76 cm2) (Moor Instruments,
Axminster, UK) to the dorsum of the foot for 30 min. The
resultant maximum hyperaemic response was assessed by
single point laser Doppler fluximetry (Perflux Pf2: Perimed,
Jarfalla, Sweden), with eight equally spaced measurements
being made within the heated area and the mean used to
represent vasodilatory capacity, arbitrarily expressed as
volts. The foot was then lowered by 50 cm and blood flow
reassessed in the eight sites in the dependent position.
Microvascular distensibility was calculated by dividing
dependent vasodilatory capacity by horizontal vasodilatory
capacity. The mean day to day intra-participant coefficient
of variation for vasodilatory capacity in three participants
assessed on five separate occasions was 6.6%; in a male
participant assessed over a 2 year period using laser
Doppler fluximetry, it was 7.1% (2.11 [0.15] arbitrary
units, mean [SD]). MVR was calculated by dividing the
mean arterial blood pressure by vasodilatory capacity.
Endothelial function Endothelial function was assessed by
iontophoretic application of the endothelial-dependent
vasodilator acetylcholine [24]. Iontophoresis delivers the
drug of interest to the skin using a small electric charge.
Briefly, a perspex chamber, with an internal area of
0.76 cm2 available for iontophoresis, was attached to the
volar aspect of the forearm and an indifferent electrode
(hydro gel pad) attached to the wrist. An electric charge
was applied using a battery powered iontophoresis control-
ler (MIC-1; Moor instruments, Axminster, UK) to transfer
the study drug across the skin. To assess the microvascular
effect of acetylcholine, 1% acetylcholine (Miochol-E;
Novartis Pharmaceuticals, Horsham, UK) was iontophor-
esed at one site and its vehicle, mannitol (3%) (Royal
Devon and Exeter Hospital Pharmacy, Exeter, UK), was
iontophoresed at another site. The protocol involved the
application of a positive charge for five 20 s pulses of
100 µA, with a 60 s rest period between each pulse, making
a total charge of 10 mC. The skin hyperaemic response was
quantified by a laser Doppler perfusion imager (LDPI)
(LDPI Pim 2.0; Perimed, Jarfalla, Sweden). Skin hyper-
aemia was assessed at baseline and then every 40 s for
400 s after the start of the charge. The LDPI perfusion
images were saved for later off-line analysis. For each
image, the mean perfusion over the entire iontophoresed
area (0.76 cm2) was calculated with LDPI Win 2.0.9
software (Perimed) and arbitrarily expressed as volts. The
results are expressed as the peak hyperaemic response.
Resting skin perfusion was determined from baseline scan
taken at the mannitol (acetylcholine vehicle) site.
Insulin sensitivity assessments Central insulin sensitivity
was calculated by HOMA of insulin sensitivity, based on
fasting insulin and glucose levels [25]. Peripheral insulin
sensitivity was assessed using a 15 min continuous insulin
tolerance test (ITT). A bolus of 0.1 U/kg insulin (Human
Actrapid; Novo Nordisk, Crawley, UK) was administered
into a vein at the site of the antecubital fossa. Blood
samples for determination of blood glucose were taken each
minute until the blood glucose level reached 3 mmol/l or
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15 min duration was reached. The glucose samples were
measured in duplicate (YSI2300 Stat Plus; YSI Life
Sciences, Yellowsprings, OH, USA). The slope of the
blood glucose curve was used to represent insulin sensi-
tivity. Mean day-to-day intra-participant variation of the
measurement of insulin sensitivity by ITT was 18% in four
individuals studied on three separate occasions.
Haemostatic and urine assessments Standard haemostatic
and urine measurements included: HbA1c (normal range 4.0–
6.0%); fasting glucose; lipid profile (total cholesterol, HDL-
cholesterol, LDL-cholesterol and triacylglycerol); urinary
creatinine; and urinary albumin. A urine albumin excretion
rate of 20 to 200 µg/min or an albumin:creatinine ratio
≥2.5 mg/mmol (men) or ≥3.5 mg/mmol (women) was
regarded as clinical cut-off for microalbuminuria. Additional
assessments included fasting plasma insulin (0.05% cross-
reactivity with human proinsulin) (Cobas; Roche, Burgess
Hill, UK) and C-reactive protein (Vascular injury panel II
plate; Meso Scale Discovery, Gaithersburg, MD, USA).
Statistical analysis Data are presented as mean (SD) unless
stated otherwise. Fovea thickness was our primary outcome
measure, as it is the only region of the macular that is
independently associated with macular oedema [26]. As
there was no difference in fovea thickness or intraocular
pressure between right and left eye, data from both eyes
were averaged and used in subsequent data analysis.
Univariate analysis (Pearson’s or Spearman’s correlation
test, dependent on normality of data) was used to explore
whether fovea thickness was associated with the following
microvascular variables: capillary pressure, Kf, vasodilatory
capacity, MVR, microvascular distensibility, resting skin
perfusion and endothelial function. Significant associations
from univariate analysis were then further explored using
linear regression, adjusting for BMI as it is well known that
obesity influences measures of microvascular variables [27,
28] (K. M. Gooding, J. E. Tooke and A. C. Shore,
unpublished observations). With a sample size of 50, the
study was powered to detect, with up to three predictors in
a model, a large effect size (f2=0.33) at the 5% level with
90% power.
Results
Fovea thickness was within the normal range defined by
Chan et al [29] using the OCT 3000 system in all
participants. There was no evidence of diabetes-related
retinal abnormalities or ocular neurodegenerative disorders
in any of the participants. Results are presented in Table 2.
Relationships between fovea thickness and microvascular
variables Capillary pressure was significantly associated
with fovea thickness (r=0.379, p=0.027, Model 1) (Table 3).
This relationship was strengthened when the model was
adjusted for BMI (Model 2) (Fig. 1). The relationship
between capillary pressure and fovea thickness adjusted for
BMI was not explained by (1) Kf (Model 3); (2) structural
effects (vasodilatory capacity, MVR, microvascular distensi-
bility) (capillary pressure standardised beta ≥0.547, p≤0.009,
Models 6–8) (Electronic supplementary material [ESM]
Table 1); (3) resting skin perfusion (capillary pressure
standardised beta 0.599, p=0.006, Model 9) (ESM Table 1);
or (4) endothelial function (standardised beta 0.562,
p=0.008, Model 10) (ESM Table 1). Neither Kf nor any
of the other microvascular variables were independently
associated with fovea thickness. In addition, no signifi-
cant associations were observed between any of the
microvascular variables and the inner and outer quadrants
of the macular.
Explaining the relationship between fovea thickness and
capillary pressure The relationship between capillary pres-
sure adjusted for BMI and fovea thickness was not
explained by mean arterial pressure (Model 4), systolic or
diastolic blood pressure (results not shown) or by intraoc-
ular pressure (Model 5). In addition, the relationship
between capillary pressure adjusted for BMI and fovea
thickness was not explained by age (capillary pressure
Variable Mean (SD) Range
Fovea thickness (µm) 214.6 (19.9) 171–249
Intraocular pressure (mmHg) 15.1 (3.2) 10–22
Capillary pressure (mmHg) 16.6 (3.8) 11.3–26.3
Kf (10−3 ml min−1 [100 ml]−1 mmHg−1) 3.58 (0.97) 1.00–6.00
MVR (mmHg/V) 52.6 (21.3) 26.0–141
Vasodilatory capacity (V) 1.93 (0.64) 0.56–3.21
Microvascular distensibility 1.23 (0.21) 0.88–1.69
Resting skin perfusion (V) 0.18 (0.07) 0.01–0.29
Peak endothelial-dependent skin perfusion (V) 1.06 (0.27) 0.61–1.86
Table 2 Results from eye and
vascular assessments for the
entire group
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standardised beta 0.568, p=0.008), inflammation (C-
reactive protein; capillary pressure standardised beta
0.544, p=0.011), insulin sensitivity (ITT, capillary pres-
sure standardised beta −0.483, p≤0.022; HOMA, capillary
pressure standardised beta −0.489, p≤0.038), glycaemic
status (HbA1c and fasting glucose) (capillary pressure
standardised beta ≥0.545, p≤0.030) or lipids (capillary
pressure standardised beta ≥0.513, p≤0.019).
Discussion
This study has demonstrated for the first time that capillary
pressure, the key determinant of movement of fluid across a
blood vessel wall, is positively associated with fovea
thickness in non-diabetic individuals. None of the other
microvascular determinants of fluid filtration such as Kf were
associated with fovea thickness. In addition, the inner and
outer quadrants of the macular were not significantly
associated with any of the microvascular variables.
Alterations in fovea thickness (an early sign of macular
oedema) are likely to result from changes in transmural
capillary fluid movement, which is governed by the balance
of hydrostatic and oncotic forces acting across the capillary
wall, as described in Starling’s equation [30]. Capillary
pressure remained associated with fovea thickness when
adjusted for intraocular pressure as well as for BMI.
Interestingly, the addition of intraocular pressure to the
model increased the amount of variance explained by the
model from 22% to 34%. Our observation that a raised
hydrostatic capillary pressure capable of promoting fluid
filtration is associated with an increase in fovea thickness
suggests that alterations in capillary pressure may play an
instrumental role in the development of macular oedema.
This would be in keeping with the importance previously
ascribed to capillary pressure in the movement of fluid across
Table 3 Associations between fovea thickness and variables as indicated
Associations per model R2 p value for overall
model
Unstandardised beta
(SE)
Standardised
beta
p values for individual
predictors
Model 1 0.140 0.027
Capillary pressure 2.067 (0.892) 0.374 0.027
Model 2 0.215 0.021
Capillary pressure 3.166 (1.07) 0.573 0.006
BMI −1.02 (0.585) −0.338 0.091
Model 3 0.188 0.115
Capillary pressure 2.897 (1.222) 0.501 0.025
Kf −1.119 (4.799) −0.048 0.121
BMI −1.042 (0.652) −0.647 0.817
Model 4 0.280 0.018
Capillary pressure 3.470 (1.050) 0.633 0.002
BMI −1.239 (0.598) −0.416 0.047
Mean arterial blood pressure 0.405 (0.344) 0.193 0.249
Model 5 0.344 0.007
Capillary pressure 2.758 (1.11) 0.499 0.019
BMI −0.999 (0.555) −0.342 0.083
Intraocular pressure 1.867 (1.012) 0.303 0.076
Fig. 1 Association between capillary pressure and fovea thickness.
Each marker represents an individual participant. Continuous line,
regression line between capillary pressure and fovea thickness (r=0.379,
p=0.027); dashed line, regression line between capillary pressure and
fovea thickness when adjusted for BMI (r=0.463, p=0.021)
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the healthy vessel wall, as capillary pressure is known to be
the most variable of Starling’s forces. These observations
suggest that when it comes to potential preventative or
therapeutic targets, attention should be directed at the
mechanisms determining retinal microvascular pressure.
Microvascular filtration capacity, a component of Starling’s
equation governing fluid filtration, was not associated with
fovea thickness and also did not contribute to the relationship
between capillary pressure and fovea thickness. Fovea
thickness is thus independent of changes in the surface area
available for exchange and permeability of the vessel wall
(hydraulic conductance), which determine Kf in non-diabetic,
healthy individuals. This observation that structural changes
in the microvasculature are not associated with fovea
thickness, either independently or in conjunction with
capillary pressure, is supported by the lack of relationship of
vasodilatory capacity, MVR and microvascular distensibility
with fovea thickness in this study. Resting skin perfusion and
endothelial function were not associated with fovea thickness.
In addition, they did not account for the effect of capillary
pressure on fovea thickness, suggesting that this relationship
is independent of microvascular skin perfusion.
Acute alterations in fovea thickness have been reported
in connection with posture in type 2 diabetes patients with
clinically significant macular oedema (CSMO), with the
fovea being thicker in the morning and decreasing in
thickness during the day and evening [31, 32]. Posture-
induced changes in hydrostatic pressure have been pro-
posed to account for these alterations. This is supported by
the observation that fovea thickness decreased by a greater
magnitude in individuals in the sitting position than in those
in the supine position over the course of the day [33].
Changes in venous and capillary pressure are believed to be
the main contributors to posture-induced alterations in fovea
thickness in type 2 diabetic patients with CSMO [32, 33].
The data in the present study support the importance of
capillary pressure in regulation of fovea thickness as was
hypothesised in these studies of postural aspects.
Systemic blood pressure did not contribute to the relation-
ship between capillary pressure and fovea thickness, as the
relationship remained when controlling for mean, systolic and
diastolic arterial blood pressure. This finding is not unexpect-
ed as in healthy individuals capillary pressure is independent
of arterial blood pressure due to the autoregulation that
protects the microcirculation from acute upstream changes in
pressure [34]. In contrast, the posture-induced changes to
fovea thickness in type 2 diabetic individuals with CSMO
have been shown to be independent and dependent of
systemic arterial blood pressure [32, 33]. A possible
explanation for the potential contribution of arterial blood
pressure to posture-induced changes in fovea thickness is a
failure of autoregulation in type 2 diabetic patients with
retinopathy and macular oedema [35].
Body composition, as reflected by BMI, influenced the
relationship between capillary pressure and fovea thickness,
as capillary pressure explained more of the variance in fovea
thickness when controlling for BMI. This suggests that BMI
may mask the effects of capillary pressure on fovea
thickness. In fact, there was a consistent trend for increased
BMI to be associated with a reduction in fovea thickness. A
potential explanation of the negative relationship between
BMI and fovea thickness is neurodegeneration, which is
associated with obesity [36]. Fovea thickness is reduced in
individuals with multiple sclerosis [37]. It is also negatively
related to duration of diabetes in type 2 diabetic patients
with no or mild retinopathy, a finding thought to reflect
neurodegeneration in the diabetic retina [38].
A limitation of the current study is the potential for a
type 2 error. However, the fact that capillary pressure was
consistently associated with fovea thickness in all models
endorses the proposal that an increase in capillary pressure
is associated with an increase in fovea thickness.
In summary, this study has shown for the first time that
capillary pressure, the key determinant of fluid filtration
across the blood vessel, is associated with fovea thickness
in non-diabetic individuals. This relationship is independent
of arterial and intraocular pressure, BMI, microvascular
skin perfusion, Kf, structural changes in the microvasculature,
inflammation, glycaemic status, insulin sensitivity and lipids.
Thus, our findings support the concept that preclinical
changes in microvascular function may be linked with end-
organ damage, in this case fovea thickness. They also suggest
that in terms of potential preventative or therapeutic targets,
attention should be directed at the mechanisms determining
retinal microvascular pressure.
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